CAR-T cells for active ANCA vasculitis
Part of Heart & circulation, Immune system & allergy, Infections clinical trials.
This trial tests a new type of cell therapy called anti-CD19 CAR-T cells for people with active ANCA vasculitis that hasn't gotten better with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of GPA or MPA type ANCA vasculitis with specific antibodies in your blood.
- Your vasculitis is currently active (BVAS score 3 or higher).
- You have tried standard treatments like rituximab or cyclophosphamide without enough benefit or had side effects.
- You do not have severely low blood counts, severe organ damage, or certain infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
This trial tests a new CAR-T cell treatment (rapcabtagene autoleucel) for people with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). It aims to see if this therapy can help control the disease by targeting certain immune cells.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial tests a new treatment called CT1192 for a type of blood vessel inflammation called ANCA-associated vasculitis. It is for people whose standard treatments have not worked or whose disease has come back. The goal is to see if CT1192 is safe and helps control the disease.
Hear when a new ANCA-IgG-positive ANCA Associated Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.